CVAC Relative Valuation
CVAC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CVAC is overvalued; if below, it's undervalued.
Historical Valuation
CureVac NV (CVAC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -9.78. The fair price of CureVac NV (CVAC) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 5.12 USD , CureVac NV is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：5.12
Fair
Undervalued
-8.66
PE
1Y
3Y
5Y
Trailing
Forward
-5.51
EV/EBITDA
CureVac NV. (CVAC) has a current EV/EBITDA of -5.51. The 5-year average EV/EBITDA is -10.10. The thresholds are as follows: Strongly Undervalued below -36.34, Undervalued between -36.34 and -23.22, Fairly Valued between 3.01 and -23.22, Overvalued between 3.01 and 16.13, and Strongly Overvalued above 16.13. The current Forward EV/EBITDA of -5.51 falls within the Historic Trend Line -Fairly Valued range.
-5.52
EV/EBIT
CureVac NV. (CVAC) has a current EV/EBIT of -5.52. The 5-year average EV/EBIT is -2.32. The thresholds are as follows: Strongly Undervalued below -41.47, Undervalued between -41.47 and -21.90, Fairly Valued between 17.25 and -21.90, Overvalued between 17.25 and 36.83, and Strongly Overvalued above 36.83. The current Forward EV/EBIT of -5.52 falls within the Historic Trend Line -Fairly Valued range.
12.17
PS
CureVac NV. (CVAC) has a current PS of 12.17. The 5-year average PS is 30.72. The thresholds are as follows: Strongly Undervalued below -55.38, Undervalued between -55.38 and -12.33, Fairly Valued between 73.77 and -12.33, Overvalued between 73.77 and 116.82, and Strongly Overvalued above 116.82. The current Forward PS of 12.17 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
CureVac NV. (CVAC) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.21. The thresholds are as follows: Strongly Undervalued below -66.93, Undervalued between -66.93 and -35.57, Fairly Valued between 27.16 and -35.57, Overvalued between 27.16 and 58.52, and Strongly Overvalued above 58.52. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-265.57
P/FCF
CureVac NV. (CVAC) has a current P/FCF of -265.57. The 5-year average P/FCF is -3.37. The thresholds are as follows: Strongly Undervalued below -100.25, Undervalued between -100.25 and -51.81, Fairly Valued between 45.08 and -51.81, Overvalued between 45.08 and 93.52, and Strongly Overvalued above 93.52. The current Forward P/FCF of -265.57 falls within the Strongly Undervalued range.
CureVac NV (CVAC) has a current Price-to-Book (P/B) ratio of 0.91. Compared to its 3-year average P/B ratio of 1.91 , the current P/B ratio is approximately -52.22% higher. Relative to its 5-year average P/B ratio of 5.28, the current P/B ratio is about -82.71% higher. CureVac NV (CVAC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -26.05%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -21.33% , the current FCF yield is about -100.00% lower.
0.91
P/B
Median3y
1.91
Median5y
5.28
-12.46
FCF Yield
Median3y
-26.05
Median5y
-21.33
Competitors Valuation Multiple
The average P/S ratio for CVAC's competitors is 0.71, providing a benchmark for relative valuation. CureVac NV Corp (CVAC) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -89.04%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CVAC increased by 50.15% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 68.44 to 504.73.
The secondary factor is the Revenue Growth, contributed -89.04%to the performance.
Overall, the performance of CVAC in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is CureVac NV (CVAC) currently overvalued or undervalued?
What is CureVac NV (CVAC) fair value?
How does CVAC's valuation metrics compare to the industry average?
What is the current P/B ratio for CureVac NV (CVAC) as of Dec 05 2025?
What is the current FCF Yield for CureVac NV (CVAC) as of Dec 05 2025?
What is the current Forward P/E ratio for CureVac NV (CVAC) as of Dec 05 2025?